1 Running Header: Alzheimer’s Disease Treatment for an Alzheimer’s Patient NURS 6330 Advanced Psychopharmacology Walden University Kizzie Houston August 4, 2019
2 Running Header: Alzheimer’s Disease Introduction Alzheimer’s disease is a progressive, irreversible neurodegenerative disease that affects more than 36 million people word wide (Jabir, Khan, & Tabrez, 2018). According to Jabir et al., AD 60-80% of all dementia diagnoses are patients with Alzheimer’s disease. There is no cure for Alzheimer’s disease. There are two types of drugs FDA approved to treat Alzheimer’s disease and they are cholinesterase inhibitors (Aricept, Razadyne, and Exelon) and modulate N-methyl- D- aspartate or NMDA (ex. Namenda). NMDA is only used if the patient is unable to tolerate cholinesterase. A 76-year-old presents with personality changes, partially oriented to place but disoriented to time, and confused. His son reports his behavior started a few years ago. He also reports his dad has trouble finding the right words. During the interview he became agitated and he stood up to leave but when the patient walked toward the door, the practitioner the patient where he was going, and he didn’t know. The purpose of this paper is to discuss the decision to treat a patient with Alzheimer’s disease and the ethical considerations. Decision #1 This decision point involved medication selection. The drugs in this decision tree are all used to manage symptom progression of early to moderate Alzheimer’s disease (Mayo Clinic, 2018). The medication choices in decision point one include Aricept, Exelon, and Razadyne. All of these medications belong to a drug classification group called cholinesterase inhibitors.
You've reached the end of your free preview.
Want to read all 5 pages?